Skip to main content
logo
Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.30
-0.46 (-1.88%)
Mar 3, 2026, 2:27 PM EST - Market open

Arcutis Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
372.07166.5429.193.69-
Other Revenue
43030.42--
Revenue
376.07196.5459.613.69-
Revenue Growth (YoY)
91.34%229.73%1517.09%--
Cost of Revenue
36.719.134.990.75-
Gross Profit
339.38177.4154.622.93-
Selling, General & Admin
274.55229.39185.15122.1260.97
Research & Development
77.0576.42110.58182.44145.56
Operating Expenses
351.6305.81295.72304.56206.53
Operating Income
-12.23-128.4-241.1-301.63-206.53
Interest Expense
-12.08-27.17-29.71-15.65-
Interest & Investment Income
8.916.1312.525.820.17
Other Non Operating Income (Expenses)
0.440.05-0.73--
Pretax Income
-14.97-139.39-259.03-311.46-206.36
Income Tax Expense
1.170.653.11--
Net Income
-16.14-140.04-262.14-311.46-206.36
Net Income to Common
-16.14-140.04-262.14-311.46-206.36
Shares Outstanding (Basic)
127121695549
Shares Outstanding (Diluted)
127121695549
Shares Change (YoY)
5.19%74.53%25.94%11.39%38.52%
EPS (Basic)
-0.13-1.16-3.78-5.66-4.18
EPS (Diluted)
-0.13-1.16-3.78-5.66-4.18
Free Cash Flow
-6.31-112.3-247.49-258.05-175.62
Free Cash Flow Per Share
-0.05-0.93-3.57-4.69-3.56
Gross Margin
90.24%90.27%91.63%79.54%-
Operating Margin
-3.25%-65.33%-404.49%-8183.04%-
Profit Margin
-4.29%-71.25%-439.79%-8449.76%-
Free Cash Flow Margin
-1.68%-57.14%-415.20%-7000.76%-
EBITDA
-7.56-126.44-240.35-300.69-206.08
EBITDA Margin
-2.01%-64.33%---
D&A For EBITDA
4.671.960.750.930.45
EBIT
-12.23-128.4-241.1-301.63-206.53
EBIT Margin
-3.25%-65.33%---
Revenue as Reported
376.07196.5459.613.69-
Advertising Expenses
25.36.911.21.5-
Updated Feb 25, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q